Dr. Harriet Kamendi is a graduate of Howard University’s Department of Pharmacology. Her research focused on characterizing the consequences of nicotine addiction on cardiovascular function using molecular and pharmacological tools to characterize the expression and regulation of nicotinic acetylcholine receptors in cardiovascular control centers of the brain. Following graduation she pursued postdoctoral studies at George Washington University where she successfully characterized the molecular determinants of sudden infant death syndrome a consequence of smoking during pregnancy.
In 2008 she joined AstraZeneca pharmaceuticals in Delaware and Massachusetts where she served as study director/senior scientist on the validation of a combined integrative pharmacology and toxicology model for screening new compounds early in development. The project successfully reduced, refined and replaced excess animal use in safety and risk assessment and decreased costs by 90%. In 2013, she left AstraZeneca following restructuring and spent two years conducting environmental chemical risk assessment projects for private companies and for the Department of Environment, State of Maryland before returning briefly to Pharma as the resident toxicologist and manager of non-clinical Development at Emergent Biosolutions, Gaithersburg, MD in 2016. Dr. Kamendi managed all aspects of projects from inception, design, identifying CRO partners, conducting quality audits, monitoring ongoing studies, interpreting study results, reporting and presenting findings to DOD partners. She left Emergent following restructuring in July of 2017 and returned to consulting. Since then she has been providing consulting services to multiple clients Scitech Ltd a DOD subcontractor based in Aberdeen, MD and 2) cannabidiol efficacy in chronic pain management for BioRemedies and Rx Remedies, Maiden Biosciences based in Baltimore MD.
Dr. Kamendi also teaches Regulatory Affairs and Biotechnology at the local colleges and community groups.